$IONS SEC Filings

Filed On	Filing
23 Oct 2026	8-K: Regulation FD Disclosure; Other Events Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
21 Oct 2026	8-K: Regulation FD Disclosure; Other Events – Approval based on Phase 3 data showing unprecedented functional cure rates compared to standard of care –
19 Oct 2026	Form 4: Devers Shannon L., EVP, Chief Human Resources Ofc Received 2,820 shares by exercise or conversion · Sold 1,357 shares ($59.1K)
19 Oct 2026	Form 4: Swayze Eric, EVP Research Received 125 shares by exercise or conversion · Sold 53 shares ($2.31K)
16 Oct 2026	144
23 Sep 2026	8-K: Regulation FD Disclosure; Other Events – Sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential –
04 Sep 2026	8-K: Regulation FD Disclosure; Other Events
04 Sep 2026	8-K: Regulation FD Disclosure; Other Events
02 Sep 2026	Form 4: Bennett C Frank, EVP, Chief Scientific Officer Acquired 110 shares (Other Transaction) ($5.64K)
02 Sep 2026	Form 4: O'neil Patrick R., EVP CLO & General Counsel Acquired 63 shares (Other Transaction) ($3.23K)
02 Sep 2026	Form 4: Monia Brett P, Director Acquired 98 shares (Other Transaction) ($5.03K)
02 Sep 2026	Form 4: Birchler Brian, EVP, Corp and Development Ops Acquired 58 shares (Other Transaction) ($2.98K)
31 Jul 2026	Form 4: Hayden Michael R, Director Bought 15,000 shares ($801K) · Bought 5,000 shares ($258K)
31 Jul 2026	S-8
29 Jul 2026	IONIS PHARMACEUTICALS, INC. 10-Q 06-30-2026
29 Jul 2026	8-K: Results of Operations and Financial Condition
17 Jul 2026	Form 4: Reikes Peter N, Director Granted 3,399 Restricted Stock Unit
17 Jul 2026	Form 4: Hantson Ludwig, Director Granted 3,399 Restricted Stock Unit
17 Jul 2026	Form 4: Herman Joan E, Director Received 5,220 shares by exercise or conversion
17 Jul 2026	Form 4: Berthelsen Spencer R, Director Received 5,220 shares by exercise or conversion

Comments